VJOncology: ChemoID trial shows increased survival for glioma patients
UC's Soma Sengupta discusses study results at recent conference
A new collaborative Phase III trial has shown increased survival for patients with recurrent high-grade glioma (HGG), a type of fast-spreading brain tumor.
Soma Sengupta, MD, PhD, was interviewed discussing the results of the trial at the American Association for Cancer Research Meeting 2022 with Pier Paolo Claudio, MD, PhD, the inventor of the ChemoID assay, which is CLIA-certified for glioblastoma. Claudio is a professor at the University of Mississippi, and the two were featured by the Video Journal of Oncology (VJOncology).
The trial examined the effectiveness of a platform called ChemoID, a cancer stem cell test. ChemoID is an actionable tool doctors can use to help determine which treatment is most effective for an individual patient's particular type of tumor.
ChemoID highlights which cancer stem cells are responsible for the tumor coming back or growing, so doctors can then choose a therapy that targets those particular stem cells. The platform was compared against the typical standard where physicians choose what they think will be the best therapy.
"The study was amazing in that most recurrent high grade glioma trials don't show an improvement in survival, but this one showed a three and a half month improvement in survival," said Sengupta, University of Cincinnati associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist, funded by the Harold C. Schott Endowed Chair in Molecular Therapeutics (Neurosurgery) and the Pam and Tom Mischell Funds.
Once the research is accepted and published, the ChemoID platform can be implemented in clinical pathology laboratories.
Watch the VJOncology interview.
Sengupta and Claudio were also featured in a VJOncology video discussing other potential methods for prolonging the life of HGG patients. Watch the second interview.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Tariff troubles for online shoppers
December 16, 2025
This year’s new regulations on tariffs and customs are leaving holiday shoppers with unexpected fees on some of their purchases, according to recent reporting by WLWT. Associate Dean of Impact and Partnerships for the University of Cincinnati’s Lindner College of Business Charles Sox spoke to WLWT about why shoppers are only just now feeling the impact, despite these policies being in effect for months.
Limited IT support offered during winter season days
December 16, 2025
The IT Service Desk, powered by Digital Technology Solutions (DTS), will be closed from Wednesday, Dec. 24, through Thursday, Jan. 1, during the university’s Winter Season Days closure. The Service Desk will resume normal operations Friday, Jan. 2.
UC sees record federal investment in engineering
December 16, 2025
The College of Engineering and Applied Science at the University of Cincinnati received a record $50.1 million in federal grant awards in the last fiscal year.